The synthetic lethality-based drugs and targets market is projected to grow at an annualized By Root

Roots Analysis has done a detailed study on “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 485+ page report, which features 195+ figures and 200+ tables, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-/267.html

Key Market Insights

An analysis of recent activity on Twitter confirms the rising interest in this domain as stakeholders attempt to harness the therapeutic potential of synthetic lethality
About 75 drug candidates based on synlet gene pairs are being evaluated for the treatment of various types of cancers; presently, there are over 20 screening platforms enabling therapy development efforts
The pipeline features both small molecules and biologic drugs based on different synlet targets for treating a variety of oncological and non-oncological indications
Innovation in this domain is evident across the plethora of scientific articles published in prestigious journals, highlighting key focus areas and prevalent / upcoming trends
Over time, several non-profit organizations have extended financial support to aid research efforts in this domain; the current focus appears to be on the identification of novel synlet targets across different clinical conditions
Significant advances in research have led to the discovery of a wide array of synlet targets; over time, substantial intellectual capital has been generated and validated by eminent scientists from renowned research institutes
To support innovation, several private and public investors have made substantial capital investments, totalling to approximately USD 5.1 billion, across 100 instances of funding
The personalized approach offered by companion diagnostics presents enormous opportunities for drug developers to partner with diagnostic test providers to improve patient / subject selection in clinical trials
Future growth of the market is likely to be driven by the success of clinical outcomes of late-stage molecules; industry stakeholders are optimistic about the vast potential of PARP inhibitors
In the mid to long term, the anticipated market opportunity is likely to be well distributed across advanced cancer indications, delivery routes and various global regions